Vertex Pharmaceuticals (VRTX) said Thursday that Health Canada accepted for review its new drug submission for suzetrigine for the treatment of moderate-to-severe acute pain in adults.
Suzetrigine is an investigational, oral, selective NaV1.8 pain signal inhibitor and represents a new class of oral pain medicine that is neither an opioid nor a nonsteroidal anti-inflammatory drug, the company said.
The company added that it intends for the regulatory review of suzetrigine to be part of an aligned review with Canadian Health Technology Assessment Organizations, including Canada's Drug Agency and Quebec's Institut national d'excellence en sante et en services sociaux.
Suzetrigine was approved by the US Food and Drug Administration under the brand name Journavx in January 2025 and received breakthrough therapy, fast track and priority review designations, the biotechnology company said.
Price: $432.66, Change: $+2.22, Percent Change: +0.52%